CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The PRECIOUS project aims to enhance cancer treatment through the development of biodegradable nanomedicines for precision immunotherapy. It focuses on creating non-toxic nanoparticles that stimulate immune responses and reverse tumor-induced immunosuppression, ultimately leading to a Phase I clinical trial.
PRECIOUS aims at scaling-up biodegradable nanomedicines for multimodal precision cancer immunotherapy.With 3.5 million cancer patients in Europe every year, new cancer medicines are eagerly awaited, notably for prostate and ovarian cancer.Systemically applied new immunotherapies are promising, but their toxicity is a hurdle.
Vaccination against cancer is safe but rather the efficacy can be disappointing, i.e. the microenvironment shuts down anti-tumour immunity.PRECIOUS will tackle 2 bottlenecks…
STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, Essen
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Belgium, GOSSELIES
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
United Kingdom, LONDON
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Poland, WARSZAWA
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
